Patient-Reported Outcomes in Orphan Drug Labels Approved by the US FDA

Value in Health - United Kingdom
doi 10.1016/j.jval.2019.03.010
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Beyond the FDA PRO Guidance: Steps Toward Integrating Meaningful Patient-Reported Outcomes Into Regulatory Trials and US Drug Labels

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

From the FDA: Epilepsy Drug Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1994English

Analysis of the Ultra-Orphan Drugs Approved by the Fda in the Period 1983-2014

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

A Review on the Drugs Approved by US-FDA and DCGI

TEXILA INTERNATIONAL JOURNAL OF CLINICAL RESEARCH
2016English

FDA Reported Use of Patient Experience Data in 2018 Drug Approvals

Therapeutic Innovation and Regulatory Science
PharmacologyPublic HealthEnvironmentalToxicologyPharmaceuticsOccupational Health
2019English

Patient-Reported Outcome Claims in European and United States Orphan Drug Approvals

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Drug Development Process and Novel Drugs Approved by FDA for 2017 -18

Applied Clinical Research, Clinical Trials and Regulatory Affairs
2018English

Measurement of Patient-Reported Outcomes. 2: Are Current Measures Failing Us?

Journal of Medical Economics
Health Policy
2019English

Responder Definition of a Patient-Reported Outcome Instrument for Laryngopharyngeal Reflux Based on the US FDA Guidance

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy